SCHEMBL2918065

SCHEMBL2918065

COCC1CCNCCN1C

nearest known ligand 0.39

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CHRNB4 P30926 2/20 0.34
CHRNA3 P32297 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
CYP2D6 P10635 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
SLC6A3 Q01959 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2917550 0.83 MEN1 (0.36) CHRNB4CHRNA3MEN1KMT2ACYP2D6
SCHEMBL15134687 0.82 SLC6A2 (0.41) MEN1KMT2ACYP2D6SLC6A2SLC6A4
SCHEMBL3436800 0.82 SLC6A2 (0.41) MEN1KMT2ACYP2D6SLC6A2SLC6A4
SCHEMBL1922084 0.82 SLC6A2 (0.41) MEN1KMT2ACYP2D6SLC6A2SLC6A4
Hydrochloric Acid SCHEMBL9582248 0.81 CYP2D6 (0.40) MEN1KMT2ACYP2D6SLC6A2SLC6A4
Hydrochloric Acid SCHEMBL31535360 0.81 CYP2D6 (0.40) MEN1KMT2ACYP2D6SLC6A2SLC6A4
Hydrochloric Acid SCHEMBL31535515 0.81 CYP2D6 (0.40) MEN1KMT2ACYP2D6SLC6A2SLC6A4
Hydrochloric Acid SCHEMBL16195604 0.81 CYP2D6 (0.40) MEN1KMT2ACYP2D6SLC6A2SLC6A4
SCHEMBL23868178 0.79
SCHEMBL20715280 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1591443-B1 PYRAZOLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-08-25 EP disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US disclosed
US-20080125409-A1 1,5-Diheterocycle-1H-Triazole Derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-05-29 US disclosed
US-20080064682-A1 Pyrazole Derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-13 US disclosed
US-20070254881-A1 Pyrazole Derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-11-01 US disclosed
EP-1803719-A1 1,5-DIHETEROCYCLE-1H-TRIAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-07-04 EP disclosed
EP-1785418-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-05-16 EP disclosed
EP-1762568-A1 PYRAZOLE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-14 EP disclosed
US-20060189591-A1 Five-membered heterocyclic derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-08-24 US disclosed
US-20060128685-A1 Pyrazole derivative DAIICHI PHARMACEUTICAL CO., LTD., (JP) 2006-06-15 US disclosed
EP-1621537-A1 FIVE-MEMBERED HETEROCYCLIC DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-02-01 EP disclosed
EP-1591443-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125409-A1 1,5-Diheterocycle-1H-Triazole Derivative PTGS1, PTGER1, TBXA2R CHRNB4 4589/4885CHRNA3 3311/4885MEN1 2370/4885
US-20070254881-A1 Pyrazole Derivative PTGER1, PTGS1, PTGER2 CHRNB4 4629/4885CHRNA3 3663/4885MEN1 3587/4885
US-20060128685-A1 Pyrazole derivative PTGS1, PTGS2, PTGER1 CHRNB4 4820/4885CHRNA3 4355/4885MEN1 4127/4885
US-20080064682-A1 Pyrazole Derivatives NAT1, AR, CBR3 CHRNB4 3974/4885CHRNA3 2021/4885MEN1 3847/4885
US-20060189591-A1 Five-membered heterocyclic derivative PTGS1, PTGIS, PTGS2 CHRNB4 4876/4885CHRNA3 4851/4885MEN1 2886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.